Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
AstraZeneca
Covington
Merck
Dow
Cantor Fitzgerald
Federal Trade Commission
Harvard Business School
Fuji

Generated: May 22, 2018

DrugPatentWatch Database Preview

Nuvo Pharm Company Profile

« Back to Dashboard

What is the competitive landscape for NUVO PHARM, and when can generic versions of NUVO PHARM drugs launch?

NUVO PHARM has eight approved drugs.

There are four US patents protecting NUVO PHARM drugs.

Summary for Nuvo Pharm
US Patents:4
Tradenames:6
Ingredients:6
NDAs:8

Drugs and US Patents for Nuvo Pharm

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Nuvo Pharms Inc PENNSAID diclofenac sodium SOLUTION;TOPICAL 020947-001 Nov 4, 2009 DISCN Yes No 8,618,164 ➤ Sign Up ➤ Sign Up
Nuvo Pharms Inc PENNSAID diclofenac sodium SOLUTION;TOPICAL 020947-001 Nov 4, 2009 DISCN Yes No 8,217,078 ➤ Sign Up ➤ Sign Up
Nuvo Pharm Inc SODIUM POLYSTYRENE SULFONATE sodium polystyrene sulfonate POWDER;ORAL, RECTAL 204071-002 Nov 28, 2014 RX No No ➤ Sign Up ➤ Sign Up
Nuvo Pharms Inc PENNSAID diclofenac sodium SOLUTION;TOPICAL 020947-001 Nov 4, 2009 DISCN Yes No 8,546,450 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for NUVO PHARM drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Topical Solution 1.5% ➤ Subscribe 2012-07-11
➤ Subscribe Topical Solution 2.0% ➤ Subscribe 2014-06-03

Non-Orange Book US Patents for Nuvo Pharm

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,375,412 Treatment of pain with topical diclofenac ➤ Sign Up
9,132,110 Treatment of pain with topical diclofenac ➤ Sign Up
9,415,029 Treatment of pain with topical diclofenac ➤ Sign Up
9,370,501 Treatment of pain with topical diclofenac ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
US Army
Julphar
Fuji
Daiichi Sankyo
Johnson and Johnson
UBS
Accenture
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.